COMBINATION THERAPY FOR COLORECTAL CARCINOMA

Abstract: the invention provides a method of treating a colorectal carcinoma with a combination of an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody. in some aspects, the combination comprises 480 mg of each antibody such as, for example, 480 mg of an anti-lag-3 antibody (e.g, relatlimab) and 480 mg of an anti-pd-1 antibody (e.g, nivolumab). in some aspects, the colorectal carcinoma is unresectable, advanced, or metastatic, including, for example, microsatellite stable or high microsatellite instable colorectal carcinoma.

Inventor(s): Rebecca Anne MOSS, Paul Andrew BASCIANO

CPC Classification: C07K16/2803 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250179174